Sellas Life Sciences Group is a biotechnology business based in the US. Sellas Life Sciences Group shares (SLS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.24 – a decrease of 2.36% over the previous week. Sellas Life Sciences Group employs 16 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.24 |
|---|---|
| 52-week range | $0.50 - $1.72 |
| 50-day moving average | $1.23 |
| 200-day moving average | $1.22 |
| Wall St. target price | $5.83 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.94 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.29 from 2024-11-19
| 1 week (2024-11-14) | 1.57% |
|---|---|
| 1 month (2024-10-21) | 8.40% |
| 3 months (2024-08-21) | -1.53% |
| 6 months (2024-05-21) | -9.15% |
| 1 year (2023-11-21) | 32.99% |
|---|---|
| 2 years (2022-11-21) | -50.00% |
| 3 years (2021-11-19) | 7.01 |
| 5 years (2019-11-21) | 4 |
| Gross profit TTM | $900,000 |
|---|---|
| Return on assets TTM | -129.15% |
| Return on equity TTM | -888.06% |
| Profit margin | 0% |
| Book value | $-0.25 |
| Market Capitalization | $84.9 million |
TTM: trailing 12 months
We're not expecting Sellas Life Sciences Group to pay a dividend over the next 12 months.
Sellas Life Sciences Group's shares were split on a 1:50 basis on 7 November 2019 . So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sellas Life Sciences Group shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Sellas Life Sciences Group shares which in turn could have impacted Sellas Life Sciences Group's share price.
Over the last 12 months, Sellas Life Sciences Group's shares have ranged in value from as little as $0.4986 up to $1.72. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sellas Life Sciences Group's is 2.396. This would suggest that Sellas Life Sciences Group's shares are significantly more volatile than the average for this exchange and represent a higher risk.
SELLAS Life Sciences Group, Inc. , a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co. , Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.